Clinical Trials Logo

Oligometastasis clinical trials

View clinical trials related to Oligometastasis.

Filter by:
  • Recruiting  
  • Page 1 ·  Next »

NCT ID: NCT06135714 Recruiting - Breast Cancer Clinical Trials

Metastasis-directed Therapy for Oligometastases of Breast Cancer

OLIGAMI
Start date: November 8, 2023
Phase: Phase 3
Study type: Interventional

OLIGAMI trial is a multi-institutional, two-arm, open-label, randomized controlled phase III trial being conducted with the participation of 50 hospitals belonging to Japan Clinical Oncology Group. After the first registration, all patients will be performed in a 12-week, subtype-specific, systemic therapy consisting of CDK4/6 inhibitors with hormonal therapy for luminal BC, docetaxel with trastuzumab and pertuzumab for HER2-positive BC, chemotherapy with immune checkpoint inhibitors for triple-negativeBC expressing PD-L1, and olaparib for cases harboring BRCA mutations. For other triple-negative BC, chemotherapy will be administered. If this 12-week systemic therapy does not cause any progression or complete response, patients proceed to second registration for randomization; arm A continues same systemic therapy alone, and arm B performs MDT followed by same systemic therapy. The MDT will involve either RT or surgery, and RT will involve mainly SBRT and partly conventional RT.

NCT ID: NCT05352178 Recruiting - Prostate Cancer Clinical Trials

Metastasis-directed Therapy for Oligorecurrent Prostate Cancer

SPARKLE
Start date: April 20, 2022
Phase: Phase 3
Study type: Interventional

The aim is to investigate whether the addition of short-term androgen deprivation therapy (ADT) during 1 month or short-term ADT during 6 months together with an androgen receptor targeted therapy (ARTA) to metastasis-directed therapy (MDT) significantly prolongs poly-metastatic free survival (PMFS) and/or metastatic castration-refractory prostate cancer free survival (mCRPC-FS) in patients with oligorecurrent hormone sensitive prostate cancer.

NCT ID: NCT05055583 Recruiting - NSCLC Stage IV Clinical Trials

Toripalimab in Combination With Platinum-based Chemotherapy for Mutation-negative Stage IV Oligometastatic NSCLC

Start date: August 31, 2021
Phase: Phase 2
Study type: Interventional

In recent years, immune checkpoint inhibitors targeting cytotoxic T-lymphocyte antigen-4, programmed death-1, and programmed death-ligand 1 have achieved milestones in the treatment of NSCLC, from back-line to first-line, and beyond. Is changing the standard of care for NSCLC. Currently, several phases Ⅲ clinical studies of neoadjuvant immunity combined with standard chemotherapy are underway, suggested that neoadjuvant ICI therapy is a promising way for locally advanced lung cancer. As an intermediate state in the process of tumor metastasis, Oligometastatic NSCLC patients have a better prognosis and more likely to benefit from local treatment than patients with extensive distant metastasis. However, there have been few reports of salvage surgery after ICI treatment in Oligometastatic NSCLC, and only one case has been reported to date. There is therefore a need to further gather evidence on salvage surgery after ICI.

NCT ID: NCT04787744 Recruiting - Prostate Cancer Clinical Trials

Veterans Affairs Seamless Phase II/III Randomized Trial of STAndard Systemic theRapy With or Without PET-directed Local Therapy for Oligometastatic pRosTate Cancer

VA STARPORT
Start date: July 1, 2021
Phase: Phase 2/Phase 3
Study type: Interventional

This is a prospective, open-label, multi-center seamless phase II to phase III randomized clinical trial designed to compare SST with or without PET-directed local therapy in improving the castration-resistant prostate cancer-free survival (CRPC-free survival) for Veterans with oligometastatic prostate cancer. Oligometastasis will be defined as 1-10 sites of metastatic disease based on the clinical determination of the LSI which incorporates all imaging, clinical, and pathologic data available.

NCT ID: NCT04641078 Recruiting - Prostate Cancer Clinical Trials

Stereotactic Body Radiotherapy With or Without Darolutamide for OligoRecurrent Prostate Cancer

DART
Start date: February 12, 2021
Phase: Phase 2
Study type: Interventional

The current trial will test the combination of darolutamide with SBRT, in oligometastatic recurrent hormone sensitive prostate cancer. We hypothesize that the addition of short-term darolutamide improves metastasis-free survival when added to SBRT without a detrimental impact on the QoL. Considering the large reluctance of both patients and physicians to be randomized to observation, we propose to use the historical data from previous reported randomized trials (STOMP and ORIOLE) as a comparator to explore as a secondary endpoint.

NCT ID: NCT04498767 Recruiting - Pancreatic Cancer Clinical Trials

Stereotactic Body Radiotherapy in Patients With Rare Oligometastatic Cancers (OligoRARE)

OligoRARE
Start date: June 10, 2021
Phase: N/A
Study type: Interventional

This is a randomized open-label multicentre Phase III superiority study of the effect of adding SBRT to the standard of care treatment on overall survival in patients with rare oligometastatic cancers. Patients will be randomized in a 1:1 ratio between current standard of care treatment vs. standard of care treatment + SBRT to all sites of known metastatic disease. The primary objective of this trial is to assess if the addition of stereotactic body radiotherapy (SBRT) to standard of care treatment improves overall survival (OS) as compared to standard of care treatment alone in patients with rare oligometastatic cancers.

NCT ID: NCT04221516 Recruiting - Clinical trials for Nasopharyngeal Carcinoma

Camrelizumab After Completion of Radiotherapy for Oligometastatic Nasopharyngeal Carcinoma

Start date: January 1, 2020
Phase: Phase 2
Study type: Interventional

The main purpose of this study is to see how well the experimental drug camrelizumab(SHR-1210) works in people with oligometastatic NPC who have already had locally radiotherapy for their disease. All patients will receive 200 mg of camrelizumab intravenously on Day 1 of each 21-day cycle. Patients will receive the study drug for up to 18 cycles.

NCT ID: NCT04172753 Recruiting - Breast Cancer Clinical Trials

Feasibility of Online MR-guided Radiotherapy on a 1.5T MR-Linac

Start date: May 9, 2018
Phase: N/A
Study type: Interventional

This study investigates the feasibility of imaging and treatment on a novel 1.5 T MR-Linac radiotherapy hybrid device.

NCT ID: NCT04158843 Recruiting - Breast Cancer Clinical Trials

Radical Local vs. Palliative Therapy for Breast Cancer Patientts With Ipsilateral Humerus or Sternum Oligometastasis

BOMB
Start date: May 9, 2020
Phase: N/A
Study type: Interventional

A Randomized, Open Label, Phase III Trial to Evaluate Radical Local Treatment versus Palliative Treatment for Breast Cancer Patients with Primary Ipsilateral Humerus or Sternum Oligometastasis

NCT ID: NCT04085029 Recruiting - Metastatic Cancer Clinical Trials

Role of Ablative Radiotherapy in the Management of Metastatic Disease: A Patient Data Registry

Start date: September 26, 2019
Phase:
Study type: Observational [Patient Registry]

The purpose of this study is to provide a registry of participants in order to assess the acute adverse event rates following ablative radiotherapy for metastatic disease.